S&P 500   4,185.58 (-0.47%)
DOW   32,914.42 (-0.39%)
QQQ   347.96 (-0.58%)
AAPL   178.59 (+0.73%)
MSFT   329.56 (-0.50%)
META   262.41 (-0.04%)
GOOGL   123.27 (-0.32%)
AMZN   119.99 (-1.37%)
TSLA   198.92 (-1.11%)
NVDA   383.69 (-4.34%)
NIO   7.40 (-0.13%)
BABA   79.54 (+1.11%)
AMD   119.04 (-4.97%)
T   15.78 (+0.90%)
F   12.01 (-4.61%)
MU   68.59 (-4.32%)
CGC   0.82 (-3.67%)
GE   101.01 (-1.36%)
DIS   87.99 (+0.19%)
AMC   4.51 (-2.59%)
PFE   37.96 (+2.57%)
PYPL   61.98 (-0.11%)
NFLX   394.31 (+0.34%)
S&P 500   4,185.58 (-0.47%)
DOW   32,914.42 (-0.39%)
QQQ   347.96 (-0.58%)
AAPL   178.59 (+0.73%)
MSFT   329.56 (-0.50%)
META   262.41 (-0.04%)
GOOGL   123.27 (-0.32%)
AMZN   119.99 (-1.37%)
TSLA   198.92 (-1.11%)
NVDA   383.69 (-4.34%)
NIO   7.40 (-0.13%)
BABA   79.54 (+1.11%)
AMD   119.04 (-4.97%)
T   15.78 (+0.90%)
F   12.01 (-4.61%)
MU   68.59 (-4.32%)
CGC   0.82 (-3.67%)
GE   101.01 (-1.36%)
DIS   87.99 (+0.19%)
AMC   4.51 (-2.59%)
PFE   37.96 (+2.57%)
PYPL   61.98 (-0.11%)
NFLX   394.31 (+0.34%)
S&P 500   4,185.58 (-0.47%)
DOW   32,914.42 (-0.39%)
QQQ   347.96 (-0.58%)
AAPL   178.59 (+0.73%)
MSFT   329.56 (-0.50%)
META   262.41 (-0.04%)
GOOGL   123.27 (-0.32%)
AMZN   119.99 (-1.37%)
TSLA   198.92 (-1.11%)
NVDA   383.69 (-4.34%)
NIO   7.40 (-0.13%)
BABA   79.54 (+1.11%)
AMD   119.04 (-4.97%)
T   15.78 (+0.90%)
F   12.01 (-4.61%)
MU   68.59 (-4.32%)
CGC   0.82 (-3.67%)
GE   101.01 (-1.36%)
DIS   87.99 (+0.19%)
AMC   4.51 (-2.59%)
PFE   37.96 (+2.57%)
PYPL   61.98 (-0.11%)
NFLX   394.31 (+0.34%)
S&P 500   4,185.58 (-0.47%)
DOW   32,914.42 (-0.39%)
QQQ   347.96 (-0.58%)
AAPL   178.59 (+0.73%)
MSFT   329.56 (-0.50%)
META   262.41 (-0.04%)
GOOGL   123.27 (-0.32%)
AMZN   119.99 (-1.37%)
TSLA   198.92 (-1.11%)
NVDA   383.69 (-4.34%)
NIO   7.40 (-0.13%)
BABA   79.54 (+1.11%)
AMD   119.04 (-4.97%)
T   15.78 (+0.90%)
F   12.01 (-4.61%)
MU   68.59 (-4.32%)
CGC   0.82 (-3.67%)
GE   101.01 (-1.36%)
DIS   87.99 (+0.19%)
AMC   4.51 (-2.59%)
PFE   37.96 (+2.57%)
PYPL   61.98 (-0.11%)
NFLX   394.31 (+0.34%)
NASDAQ:EPIX

ESSA Pharma (EPIX) Stock Forecast, Price & News

$3.01
+0.08 (+2.73%)
(As of 03:21 PM ET)
Compare
Today's Range
$2.80
▼
$3.01
50-Day Range
$2.60
▼
$3.15
52-Week Range
$1.40
▼
$5.92
Volume
20,083 shs
Average Volume
155,281 shs
Market Capitalization
$132.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

ESSA Pharma MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
498.6% Upside
$17.00 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.13mentions of ESSA Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.75) to ($1.00) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

819th out of 1,006 stocks

Pharmaceutical Preparations Industry

410th out of 492 stocks

See Top Rated MarketRank™ Stocks Here

EPIX stock logo

About ESSA Pharma (NASDAQ:EPIX) Stock

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Stock News Headlines

May 24, 2023 | finance.yahoo.com
We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely
May 18, 2023 | finance.yahoo.com
EPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide…
May 31, 2023 | Edge On The Street (Ad)
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
May 11, 2023 | finance.yahoo.com
ESSA Pharma to Present at JMP Securities Life Sciences Conference
May 9, 2023 | msn.com
ESSA Pharma: Q2 Earnings Insights
May 9, 2023 | finance.yahoo.com
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023
April 18, 2023 | finance.yahoo.com
ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 15, 2023 | ca.finance.yahoo.com
ESSA Pharma Inc. (EPIX)
May 31, 2023 | Edge On The Street (Ad)
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
April 12, 2023 | finance.yahoo.com
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer
March 8, 2023 | finance.yahoo.com
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023 | finance.yahoo.com
ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures
February 23, 2023 | finance.yahoo.com
EPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide…
February 7, 2023 | finance.yahoo.com
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022
February 2, 2023 | finance.yahoo.com
ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference
January 25, 2023 | finance.yahoo.com
A Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)
December 15, 2022 | finance.yahoo.com
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate
December 13, 2022 | msn.com
ESSA Pharma GAAP EPS of -$0.14
December 13, 2022 | finance.yahoo.com
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022
November 15, 2022 | finance.yahoo.com
EPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide…
November 10, 2022 | finance.yahoo.com
ESSA Pharma to Participate in Two Upcoming Investor Conferences
October 31, 2022 | finance.yahoo.com
J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment
October 31, 2022 | finance.yahoo.com
ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials
October 26, 2022 | barrons.com
(PR) ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
October 26, 2022 | finance.yahoo.com
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
September 21, 2022 | finance.yahoo.com
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
September 6, 2022 | reuters.com
ESSA Pharma Inc
See More Headlines
Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Company Calendar

Last Earnings
5/09/2023
Today
5/31/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
9/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPIX
CUSIP
N/A
CIK
1633932
Web
www.essapharma.com
Phone
778-331-0962
Fax
604-738-4080
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+468.6%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,100,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-17.63%
Return on Assets
-17.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
73.64
Quick Ratio
73.64

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.55 per share
Price / Book
0.84

Miscellaneous

Outstanding Shares
44,090,000
Free Float
38,801,000
Market Cap
$131.83 million
Optionable
Not Optionable
Beta
2.08

Key Executives

  • Dr. David Ross Parkinson M.D. (Age 73)
    Pres, CEO & Director
    Comp: $829.56k
  • Mr. David S. Wood C.M.A. (Age 66)
    CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer
    Comp: $532.35k
  • Mr. Peter A. Virsik M.B.A. (Age 52)
    M.S., Exec. VP & COO
    Comp: $646.75k
  • Dr. Alessandra Cesano M.D. (Age 63)
    Ph.D., Chief Medical Officer
    Comp: $620.81k
  • Chandtip Chandhasin
    Exec.
  • Erica Osbourne
    Exec.
  • Erin Rudsinski
    Exec.
  • Loleta Harris
    Exec.
  • Neil Thapar
    Exec.
  • Nkengyal Barber
    Exec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













EPIX Stock - Frequently Asked Questions

What is ESSA Pharma's stock price forecast for 2023?

0 brokerages have issued twelve-month price targets for ESSA Pharma's stock. Their EPIX share price forecasts range from $17.00 to $17.00. On average, they expect the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 468.6% from the stock's current price.
View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts.

How have EPIX shares performed in 2023?

ESSA Pharma's stock was trading at $2.52 at the beginning of the year. Since then, EPIX stock has increased by 18.7% and is now trading at $2.99.
View the best growth stocks for 2023 here.

Are investors shorting ESSA Pharma?

ESSA Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 171,000 shares, a decrease of 11.2% from the April 30th total of 192,600 shares. Based on an average daily trading volume, of 75,600 shares, the days-to-cover ratio is currently 2.3 days. Approximately 0.9% of the company's shares are short sold.
View ESSA Pharma's Short Interest.

When is ESSA Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our EPIX earnings forecast.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX).

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.81%), Ally Bridge Group NY LLC (0.54%), Two Sigma Advisers LP (0.51%), Susquehanna International Group LLP (0.00%), JPMorgan Chase & Co. (0.14%) and Two Sigma Investments LP (0.11%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech.
View institutional ownership trends.

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $2.99.

How much money does ESSA Pharma make?

ESSA Pharma (NASDAQ:EPIX) has a market capitalization of $131.83 million. The company earns $-35,100,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The official website for the company is www.essapharma.com. The company can be reached via phone at 778-331-0962, via email at alada@troutgroup.com, or via fax at 604-738-4080.

This page (NASDAQ:EPIX) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -